Generic Name

Paclitaxel

Brand Names
Paclitaxel Protein-Bound, Abraxane
FDA approval date: March 01, 2004
Classification: Microtubule Inhibitor
Form: Injection

What is Paclitaxel Protein-Bound (Paclitaxel)?

Paclitaxel protein-bound particles for injectable suspension is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

There is no latest advances for this treatment

Brand Information